ERBB2 and breast carcinoma: We analyzed seven anti-HER2 agents in patients with brain metastases from breast cancer and found that trastuzumab deruxtecan significantly improved PFS in patients in the RCT study, while trastuzumab deruxtecan significantly improved ORR in patients in the single-arm study.